These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 22503290)

  • 1. Small molecule drugs - optimizing DNA damaging agent-based therapeutics.
    Hartley JA; Hochhauser D
    Curr Opin Pharmacol; 2012 Aug; 12(4):398-402. PubMed ID: 22503290
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trabectedin: novel insights in the treatment of advanced sarcoma.
    Lopez JP; Gajdos C; Elias A
    Curr Oncol Rep; 2014 Jun; 16(6):387. PubMed ID: 24756367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trabectedin: Supportive care strategies and safety profile.
    Jordan K; Jahn F; Jordan B; Kegel T; Müller-Tidow C; Rüssel J
    Crit Rev Oncol Hematol; 2015 Jun; 94(3):279-90. PubMed ID: 25794812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trabectedin mechanism of action: what's new?
    D'Incalci M
    Future Oncol; 2013 Dec; 9(12 Suppl):5-10. PubMed ID: 24195524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trabectedin and ovarian cancer: statistical trickery.
    Prescrire Int; 2011 Apr; 20(115):93. PubMed ID: 21648209
    [No Abstract]   [Full Text] [Related]  

  • 6. Trabectedin for the management of soft-tissue sarcoma.
    Boudou L; Baconnier M; Blay JY; Lombard-Bohas C; Cassier PA
    Expert Rev Anticancer Ther; 2009 Jun; 9(6):727-37. PubMed ID: 19496709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trabectedin therapy as an emerging treatment strategy for recurrent platinum-sensitive ovarian cancer.
    López-Guerrero JA; Romero I; Poveda A
    Chin J Cancer; 2015 Jan; 34(1):41-9. PubMed ID: 25556617
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trabectedin for Soft Tissue Sarcoma: Current Status and Future Perspectives.
    Gordon EM; Sankhala KK; Chawla N; Chawla SP
    Adv Ther; 2016 Jul; 33(7):1055-71. PubMed ID: 27234989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trabectedin as a chemotherapy option for patients with BRCA deficiency.
    Monk BJ; Lorusso D; Italiano A; Kaye SB; Aracil M; Tanović A; D'Incalci M
    Cancer Treat Rev; 2016 Nov; 50():175-182. PubMed ID: 27710871
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in patients with advanced ovarian cancer: exploratory analysis of the phase 3 OVA-301 study.
    Monk BJ; Ghatage P; Parekh T; Henitz E; Knoblauch R; Matos-Pita AS; Nieto A; Park YC; Cheng PS; Li W; Favis R; Ricci D; Poveda A
    Ann Oncol; 2015 May; 26(5):914-920. PubMed ID: 25722380
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The efficacy of trabectedin in treating ovarian cancer.
    Teplinsky E; Herzog TJ
    Expert Opin Pharmacother; 2017 Feb; 18(3):313-323. PubMed ID: 28140689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trabectedin has promising antineoplastic activity in high-grade meningioma.
    Preusser M; Spiegl-Kreinecker S; Lötsch D; Wöhrer A; Schmook M; Dieckmann K; Saringer W; Marosi C; Berger W
    Cancer; 2012 Oct; 118(20):5038-49. PubMed ID: 22392434
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical benefit of trabectedin in uterine adenosarcoma.
    Schroeder BA; Rodler ET; Loggers ET; Pollack SM; Jones RL
    Med Oncol; 2013 Jun; 30(2):501. PubMed ID: 23456619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trabectedin in ovarian cancer: could we expect more?
    Sessa C; D'Incalci M
    Ann Oncol; 2011 Jan; 22(1):7-8. PubMed ID: 21059638
    [No Abstract]   [Full Text] [Related]  

  • 15. Trabectedin--a targeted chemotherapy?
    von Mehren M
    Lancet Oncol; 2007 Jul; 8(7):565-7. PubMed ID: 17613417
    [No Abstract]   [Full Text] [Related]  

  • 16. Trabectedin for the treatment of breast cancer.
    D'Incalci M; Zambelli A
    Expert Opin Investig Drugs; 2016; 25(1):105-15. PubMed ID: 26592307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response to trabectedin treatment in a highly pretreated patient with an advanced meningeal hemangiopericytoma.
    Martinez-Trufero J; Alfaro J; Felipo F; Alvarez M; Madani J; Cebollero A
    Anticancer Drugs; 2010 Sep; 21(8):795-8. PubMed ID: 20622667
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Wide-spectrum characterization of trabectedin: biology, clinical activity and future perspectives.
    Vincenzi B; Napolitano A; Frezza AM; Schiavon G; Santini D; Tonini G
    Pharmacogenomics; 2010 Jun; 11(6):865-78. PubMed ID: 20504257
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trabectedin's contribution to the treatment of sarcomas.
    Blay JY
    Expert Rev Anticancer Ther; 2013 Jun; 13(6 Suppl 1):3-9. PubMed ID: 23638729
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Third-line trabectedin for a metastatic desmoplastic small round cell tumour treated with multimodal therapy.
    Brunetti AE; Delcuratolo S; Lorusso V; Palermo L; Di Giorgio A; Pisconti S; Silvestris N
    Anticancer Res; 2014 Jul; 34(7):3683-8. PubMed ID: 24982387
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.